LPCAT3 is essential for leukemia progression and represents a therapeutic vulnerability in AML
Mutian Cao, Lizhen Cong, Yifei He, Mingyue Hao, Yuanyi Ling, Wanting Li, Mingyue Zhang, Weiping Yuan, Yajing Chu · 2026
Read LPCAT3 is essential for leukemia progression and represents a therapeutic vulnerability in AML by Mutian Cao, Lizhen Cong, Yifei He, Mingyue Hao, Yuanyi Ling, Wanting Li, Mingyue Zhang, Weiping Yuan, Yajing Chu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13544681.txt.
Description
Mutian Cao and eight colleagues identify a fat-processing enzyme as vital to acute myeloid leukemia, in a study from twenty twenty-six. The enzyme, LPCAT3, remodels membrane lipids. Patient data showed too much of it in leukemia, with high levels tracking worse survival. The team held it down in leukemia cell lines.
Knocking the enzyme down stalled cell growth and triggered cell death. Cell cycles stopped at the resting phase. Forcing extra enzyme, in turn, helped cells survive. In mouse xenografts, loss of it shrank the leukemic burden. Gene activity after loss shifted toward pathways that attract granulocytes. That hints the enzyme also shapes cell maturing and the tumor surroundings. The authors name LPCAT3 as a therapy target worth pursuing.
Catalog record
| CREATOR | Mutian Cao, Lizhen Cong, Yifei He, Mingyue Hao, Yuanyi Ling, Wanting Li, Mingyue Zhang, Weiping Yuan, Yajing Chu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |